{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 41,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a comparative framework to contrast the 'Terminated' vs 'Clinical' status of competitors, with a callout box detailing the specific advantages of ERAS-007.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/39",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.58,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Terminated vs Clinical landscape",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c0f65f4-d0a3-4769-b1fc-a578b68422d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.37,
        "x": 0.61,
        "y": 0.82
      },
      "kind": "disclaimer",
      "text": "MTD: maximum tolerated dose; monotx: monotherapy; HCQ: hydroxychloroquine; CoM: composition of matter patent; ORR: overall response rate; RR: response rate; EC: encorafenib + cetuximab; RP2D: recommended Phase 2 dose; FIH: First-in-Human",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eea6dc6d-8862-4085-8dc5-5cad15b00e0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.37,
        "x": 0.61,
        "y": 0.18
      },
      "kind": "list",
      "text": "Hit-and-run profile optimizing efficacy, tolerability; Safety and tolerability established; Encouraging signs of efficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2da10e9-c25b-4d2b-9396-1820a1aaa474",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "ERAS-007: Potential best-in-class ERK1/2 inhibitor in a field marked by attrition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84bb6b66-69ad-44d3-8c97-9a1019be2927",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b7944d96-e477-432d-9394-40ada2cb7e0c",
      "evidence": "list/bullet: Hit-and-run profile optimizing efficacy, tolerability; Safety and tolerability established; Encouraging signs of efficacy",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "competitive-landscape",
      "slug": null,
      "matchId": "408493e0-d3e4-4acf-8ea8-4bbbf2eab07c",
      "evidence": "Categorization of competitors into 'Terminated' and 'Clinical' groups with specific performance metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}